Fidel Delgado, CEO of Neoalgae, published the research findings in the prestigious scientific journal Frontiers under the original title “Phaeodactylum tricornutum as a stable platform for pilot scale production and investigation of the viability of spirulina fucoxanthin as a commercial lipolysis active novel compound”. The study is included within the IMPRESS project which aims to promote the industry, based on solid scientific foundations and focused on the Bioeconomy and Blue Growth strategies of the European Union and which strives to promote sustainable and waste-free production and consumption. The article serves as the culmination of the research and as a platform for pilot-scale production as well as an investigation of the viability of spirulina fucoxanthin as a new commercial lipolysis active compound.
The publication offers insights into the nutraceutical market and its significant growth over recent years. The growth is due to the change in consumer preferences towards products of natural and ecological origin. One of the main areas of interest in this field is carotenoids derived from microalgae, whose antioxidant activity protects against oxidative damage in human cells. The diatom Phaeodactylum tricornutum has been widely studied due to its high fucoxanthin (antioxidant carotenoid) content. However, pilot and industrial-scale experiments to achieve continuous and stable production of Phaeodactylum tricornutum and extracted fucoxanthin are limited. For this reason, this research focuses on the study of fucoxanthin production, going through the cultivation stage, harvesting, scaling procedure, and encapsulation.
To read the full publication, click here.
